Clinical Trials Browser

Recruiting × OTHER × Etoposide × Clear all

NCT03418038 2026-04-16

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT07224100 2026-04-16

Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05996185 2026-04-14

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Phase 2 Recruiting

DermatologicLymphoidOther hematologic neoplasm

Recurrence, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07525466 2026-04-13

Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH)

Phase 1/2 Recruiting

LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

NCT06738368 2026-04-08

Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03583710 2026-04-07

Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence

Phase 3 Recruiting

ENSAT Stage I Adrenal Cortex Carcinoma

NCT05624996 2026-04-03

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT05957510 2026-04-03

Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT07498959 2026-03-27

TESTIGO

Phase NA Recruiting

Testicular Neoplasms, Seminoma

NCT06528691 2026-03-23

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

Phase 2 Recruiting

Glioma, Central Nervous System Neoplasms

NCT05384821 2026-03-18

MetroWilms

Phase 1/2 Recruiting

Kidney Neoplasms, Wilms Tumor

NCT07194044 2026-03-16

METTSEO

Phase 1 Recruiting

Sarcoma, Ewing

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

Phase 2 Recruiting

Burkitt Lymphoma

NCT05068232 2026-03-04

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Phase 2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04231877 2026-03-03

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Phase 1 Recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04469530 2026-02-27

AflacST1903

Phase 2 Recruiting

Other solid neoplasm

Solid Tumor

NCT06942039 2026-02-27

Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation

Phase EARLY_PHASE1 Recruiting

Medulloblastoma, Neuroblastoma, Pinealoma, Neuroectodermal Tumors, Primitive, Rhabdoid Tumor, Pyloric Stenosis, Hypertrophic

NCT01356290 2026-02-23

MEMMAT

Phase 2 Recruiting

Ependymoma, Medulloblastoma, Recurrence

NCT06830694 2026-02-23

Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT05991388 2026-02-20

Glo-BNHL

Phase 2/3 Recruiting

Lymphoma, B-Cell

NCT03136146 2026-02-17

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05535166 2026-02-12

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Phase 2 Recruiting

Brain Neoplasms, Medulloblastoma

NCT06528496 2026-02-10

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT05762419 2026-01-28

FUS Etoposide for DMG

Phase 1 Recruiting

Diffuse Intrinsic Pontine Glioma, Brain Diseases, Brain Neoplasms, Glioma, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT07097363 2026-01-15

Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT06039371 2026-01-14

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Phase 2 Recruiting

Prostatic Neoplasms

NCT05106296 2026-01-09

Chemo-immunotherapy Using Ibrutinib Plus Indoximod for Patients With Pediatric Brain Cancer

Phase 1 Recruiting

Brain Neoplasms, Ependymoma, Glioblastoma, Medulloblastoma, Neuroectodermal Tumors, Primitive

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Recruiting

Extensive Stage Small Cell Lung Cancer

NCT07141264 2025-12-30

Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy

Phase 2 Recruiting

SCLC,Extensive Stage

NCT04696575 2025-12-15

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Phase 2 Recruiting

Extensive Stage Lung Small Cell Carcinoma

NCT06091124 2025-12-08

NEOBLAST

Phase 2 Recruiting

Urinary Bladder Neoplasms

NCT04871607 2025-12-04

Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma

Phase 2 Recruiting

Hodgkin Disease

NCT04681417 2025-11-28

RETINO 2018

Phase 2/3 Recruiting

Other solid neoplasm

Retinoblastoma

NCT06937866 2025-11-21

Maintenance Zanzalintinib With Etoposide After HDCT in GCT

Phase 1/2 Recruiting

Neoplasms, Germ Cell and Embryonal

NCT05821088 2025-11-20

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07232134 2025-11-20

AML-DS-2025

Phase 3 Recruiting

Other hematologic neoplasm

Down Syndrome, Leukemia, Myeloid, Acute

NCT03125642 2025-11-04

Auto Stem Cell Transplant for Lymphoma Patients

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07059975 2025-11-04

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

Phase EARLY_PHASE1 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07002216 2025-11-03

BrECADD

Phase 2 Recruiting

Hodgkin Disease

NCT02605421 2025-10-21

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Phase 2 Recruiting

Neuroblastoma

NCT04679012 2025-10-07

Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation

Phase 2 Recruiting

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07199296 2025-09-30

Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL Treatment

Phase 2 Recruiting

Lymphoma, Mantle-Cell

NCT06838208 2025-09-24

Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC

Phase 2 Recruiting

Small Cell Lung Carcinoma

NCT06144736 2025-09-15

PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND

Phase 2 Recruiting

Seminoma

NCT07081022 2025-08-21

JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT02393157 2025-08-08

O-ICE

Phase 2 Recruiting

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03719105 2025-08-08

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

Phase EARLY_PHASE1 Recruiting

LymphoidOther hematologic neoplasm

Lymphoma, T-Cell, Peripheral, Leukemia, Large Granular Lymphocytic

NCT07109401 2025-08-07

Perioperative Immunotherapy for Resectable Limited-Stage SCLC

Phase 2 Recruiting

Perioperative Immunotherapy

NCT04268121 2025-07-23

NEONEC

Phase 2 Recruiting

EndocrineGastrointestinal

Gastrointestinal Neoplasms, Carcinoma, Neuroendocrine

NCT05312671 2025-06-29

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Phase 2 Recruiting

Urinary Bladder Neoplasms